591 results about "Intestinal microorganisms" patented technology

A database structure obtained by means of information retrieval, and a reasoning system, which structure and system specifically relate to a gut microbe knowledge graph system, comprising: a gut microbe knowledge graph consisting of a gut microbe knowledge base, a gut microbe and small-molecule drug therapy association knowledge base, and a clinical medicine database; and a multimodal uncertainty reasoning system, using the gut microbe knowledge graph. The gut microbe knowledge graph system predicts potential diseases, drugs, genes, etc., which are associated with gut microbes.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention discloses a leak-free core-shell hydrogel microsphere delivery system for non-contact flora transplantation as well as a construction method and application of the leak-free core-shell hydrogel microsphere delivery system. According to the invention, bacteria are encapsulated in a core of a core-shell microsphere through a two-step photo-initiation emulsion polymerization method of methacrylic acid gelatin, and a non-contact microbiota transplantation system (NMTS) is constructed. The NMTS can be used for biological encapsulation of various strains, shows encapsulation efficiency close to 100%, and has little influence on bacterial activity at the same time. NMTS demonstrates: a shielding effect that protects sealed bacteria from low pH values in the gastrointestinal tract and bile acid disruption; sufficient mechanical strength ensures that bacterial leakage is prevented and the infection risk is eliminated in the whole gastrointestinal tract delivery process; and internal and external substance exchange is realized, and the intestinal microorganism structure is remodeled. The invention provides a unique bacterial cell microencapsulation method which is a non-contact, safe and effective micropopulation transplantation method.

To meet the need of a novel therapy for preventing or treating pathological dysbiosis of the gut microbiota, in particular for treating or preventing neurodegenerative diseases or bowel diseases. The present invention relates to the use of a composition comprising a plurality of specific molecules for the treatment of a pathological dysbiosis of the gut microbiota. The pathological dysbiosis of the gut microbiota may be characterized by an excess amount of sulfide-producing bacteria and insufficient butyrate-producing bacteria.

The invention discloses a severe pancreatitis early-stage enteral nutrition intolerance assessment method and system based on multi-dimensional indexes, and relates to the technical field of enteral nutrition tolerance. According to the method, enteral microorganism environment parameters of a patient are monitored in real time through non-invasive detection equipment, and the enteral nutrition intolerance of the patient is evaluated by combining a multi-dimensional index parameter set; the early enteral nutrition tolerance condition of the severe pancreatitis patient can be accurately evaluated. In the steps S1 to S3, through data preprocessing and data fusion, an initial nutrition tolerance risk value and a correction value are calculated through a tolerance evaluation model, the nutrition tolerance condition of a patient can be accurately evaluated, a scientific basis is provided for medical staff to formulate a personalized nutrition support scheme, and finally a comprehensive tolerance evaluation value is obtained. The medical staff can perform primary evaluation on the enteral nutrition of the patient according to the value, and grade division is performed based on the evaluation result. And the overall nutritional status and rehabilitation speed of the patient are improved by adjusting a nutrition support scheme in a personalized manner.

The invention relates to bifidobacterium animalis subsp. Lactis C-2 with an effect of improving inflammatory bowel diseases and application of the bifidobacterium animalis subsp. Lactis C-2. The bifidobacterium animalis subsp. Lactis C-2 is classified and named as Bifidobacterium animalis subsp. Lactis, and the preservation number of the bifidobacterium animalis subsp. Lactis C-2 is GDMCC No: 65455. The bacterial strain can inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria and optimize the composition of intestinal microorganisms by regulating the intestinal microecology, repairing the intestinal mechanical barrier, improving the intestinal immune response, inhibiting oxidative stress reaction and other action mechanisms, thereby inducing anti-inflammatory response and improving the intestinal barrier function. Therefore, the bifidobacterium animalis subsp. Lactis C-2 strain is suitable for preparing the medicine with the effect of preventing, improving or treating the inflammatory bowel disease.

The present invention provides a combination comprising lactose and human milk oligosaccharides (HMOs) 2'-fucosyllactose (2'-FL), lacto- / V-neotetraose (LNnT), 3- fucosyllactose (3'-FL), at least one of 3'-sialyllactose (3'-SL) or 6'-sialyllactose (6'-SL), and optionally lacto-N-tetraose (LNT) for use in the dietary management of dysbiosis of the gut microbiota in a subject or for use in the dietary management of a disease or disorder associated with metabolism and / or accumulation of BCFA in a subject.

The present invention relates to compositions comprising a microbial consortium for treating or preventing medical disorders and pathologies through microbiome modulation, including medical disorders associated with a dysbiosis or a loss of gut microbial function.

The invention discloses a method for screening and culturing active plastic degrading bacteria based on combination of Raman spectrum and heavy water labeling, which realizes rapid screening of high-activity plastic degrading bacteria within 7 days by utilizing intestinal microorganisms under the condition of inorganic salt culture incubation with plastic as a unique carbon source. The method comprises the following steps: dissecting and homogenizing intestinal tracts of tenebrio molitor fed with plastics under a sterile condition, harvesting enteric microorganisms through iohexol density gradient centrifugation, incubating the enteric microorganisms in an inorganic salt culture solution containing heavy water and plastics to serve as a treatment group, centrifugally cleaning an incubated to-be-detected substance, and performing Raman detection, the high-activity plastic degrading bacteria can be sorted for further downstream sequencing and culture. The method is rapid, efficient, easy and convenient to operate and suitable for rapidly screening, identifying and culturing the high-activity plastic degrading bacteria from a complex natural environment, and development of plastic biodegradation and harmless treatment processes is facilitated.

The invention discloses an inulin gel compound loaded with Prussian blue nano-enzyme and nattokinase and application of the inulin gel compound in treatment of inflammatory bowel disease, the compound is formed by blending the Prussian blue nano-enzyme, the nattokinase and inulin, the Prussian blue nano-enzyme with multiple antioxidant enzyme activities is used for removing a large amount of active oxygen in cells, and the nattokinase is used for treating inflammatory bowel disease. The level of inflammatory factors is reduced, oxidative stress is relieved, and intestinal inflammation is treated; the nattokinase not only can inhibit the formation of intestinal microthrombus and effectively dissolve thrombus through the excellent thrombolysis capability of the nattokinase, but also can synergistically and effectively treat inflammatory bowel diseases through the intestinal microbiota regulation capability of the nattokinase; in addition, the inulin, the Prussian blue nano-enzyme and the nattokinase jointly realize the regulation of intestinal microbiota of the patient with the inflammatory bowel disease, so that the anxiety and depression symptoms related to the inflammatory bowel disease are effectively relieved through microbiota-intestine-brain axis. In general, the invention provides a creative example for treating the inflammatory bowel disease and related intestinal internal and external complications thereof.

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention provides a diabetes mellitus intestinal microbial marker, application thereof and a method for constructing a diabetes mellitus detection model, and belongs to the technical field of medicine and biomedicine. The method comprises the following steps: extracting biomarkers related to the pathogenesis and progress of diabetes from metagenome data, constructing a random forest model by using a random forest algorithm, and training and testing the constructed random forest model by using a training set and a test set to obtain a diabetes detection model. According to the diabetes detection model, differential bacteria of a diabetic patient and a healthy control can be identified more accurately, so that the accuracy of early auxiliary diagnosis of diabetes is improved, and the treatment effect is improved. The invention provides specific intestinal microbial markers for identifying diabetes mellitus, which reveal the change in the metabolic pathway of the host-microorganism associated with diabetes mellitus, contributing to the discovery of new biomarkers or therapeutic targets for diabetes mellitus.

The invention relates to the technical field of medical data privacy protection and information security, in particular to an obesity risk prediction report generation system and method based on a knowledge base, and the system comprises a data collection module, a risk prediction model module, a knowledge base module and a report generation module. According to the method, multi-dimensional data of intestinal microorganisms, gene detection, dietary habits, lifestyles and the like of the user are analyzed, a knowledge base and machine learning model combination technology is utilized, a personalized obesity risk assessment report can be generated, and therefore multi-dimensional and accurate obesity risk assessment is achieved.

The invention provides a drug permeability clinical prediction model, a construction method thereof and a non-specific drug permeability evaluation method, and belongs to the technical field of biological medicine. The invention provides a construction method of a drug permeability clinical prediction model. According to the construction method, intestinal microorganism characteristics are introduced into model construction for the first time. The prediction performance of the constructed LGBM model containing the intestinal microorganism characteristics in the aspect of NAC permeability prediction is superior to that of other traditional business models. The invention also provides a serine-derived sphingolipid de novo synthesis pathway, which is different from the traditional sphingolipid de novo synthesis pathway, and is named as a cysteine sphingolipid metabolism pathway, NAC-derived cysteine may participate in the biosynthesis of microbial sphingolipid through covalent binding with palmitoyl-CoA, thereby damaging intestinal permeation of NAC.

The invention provides a myocardial amyloidosis classification prediction method and system based on cardiac magnetic resonance multi-sequence radiomics, and is applied to the technical field of data processing. The method comprises the following steps: preprocessing cardiac magnetic resonance multi-sequence image information to generate a standardized multi-sequence image data set; processing the standardized multi-sequence image data set to generate a target image omics feature vector; processing the gene detection information to generate pathogenic gene characteristics and mutation type characteristics; processing the target radiomics feature vectors and the cardiac magnetic resonance parameters based on medical knowledge graph data to generate an AL type myocardial feature associated feature set and an ATTR type myocardial feature associated feature set; processing the blood detection index information and the intestinal microflora parameter information to generate myocardial amyloidosis influence factors; and processing the data based on the target myocardial amyloidosis classification prediction model to generate a myocardial amyloidosis classification prediction result.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

The present invention relates to novel lactic acid bacteria, Bifidobacterium bifidum P61 KCCM13367P, Lactobacillus paracasei P62 KCCM13368P, or a mixture thereof. The novel lactic acid bacteria and the mixture thereof of the present invention change the composition of intestinal microorganisms to inhibit the expression of sarcopenia markers (MuRF-1, MAFbx / Atrogin-1, etc.), increase muscle strength and muscle mass, and promote muscle formation, thereby alleviating sarcopenia. In addition, the present invention improves cognitive dysfunction by inhibiting behavior similar to cognitive dysfunction and regulating the expression of factors (BDNF, IL-10, etc.) associated with said dysfunction. In addition, the present invention has the effect of treating inflammation by reducing the expression of inflammatory markers (TNF-α, IL-6, IL-1ß, and MPO) and increasing the expression of an anti-inflammatory marker (IL-10).

The invention discloses a brain glioma intestinal microbial marker, a product and application of the brain glioma intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing brain glioma and a computer program product related to the brain glioma. The product provided by the invention has good feasibility and accuracy, and provides a new tool for clinical diagnosis.

The invention discloses application of Prevotella copri as a children's metabolism-related fatty liver disease (MASLD) biomarker and a therapeutic target, relates to the fields of medical microbiology and metabonomics, and explores biological characteristics of the Prevotella copri and an action mechanism of the Prevotella copri in children's metabolism-related fatty liver disease (MASLD). The invention also analyzes the effect of Prevotella copri and its metabolite 5-aminovaleric acid in the development of children's metabolism-related fatty liver disease (MASLD), and provides a basis for developing a method for treating metabolism-related fatty liver disease (MASLD) based on intestinal microorganisms. According to the present invention, the Prevotella copri is subjected to intragastric administration to the mouse fed with the high fat diet, such that the liver fat change and the intestinal flora disorder aggravating are found; the metabolite 5-amino valeric acid of the Prevotella copri can be used for aggravating the adiposis of the liver cells. Therefore, the Prevotella copri and the metabolite 5-aminovaleric acid of the Prevotella copri can be used as a biomarker and a therapeutic target for diagnosis, treatment, prognosis evaluation or drug screening of the MASLD (Metabolism-related Fatty Liver Disease) of children.

Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum GL-2 and application thereof. The invention provides a strain of lactobacillus plantarum which is preserved in the 8th road of Wuchang District in Wuhan City, Hubei Province on March 15, 2023, and the preservation number is CCTCC M 2023328. The results of the embodiment show that the lactobacillus plantarum GL-2 provided by the invention has the effects of reducing blood sugar and blood fat, and the lactobacillus plantarum GL-2 provided by the invention also has the effects of repairing inflammation damaged organs and regulating intestinal microorganisms.

A nutritional composition comprising sn-2 palmitic acid and A2 beta-casein for use in improving the gut microbiota in a human subject.

The invention discloses application of animal bifidobacterium subsp. Lactis GOLDGUT-BB21 in preparation of products for relieving depression, and belongs to the technical field of biological medicine. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention relates to the field of microorganisms, in particular to a microorganism single cell sorting, collecting and culturing method. The LIFT single cell separation technology and the Raman spectrum technology are combined, rapid identification and culture of specific microorganism single cells in a complex sample are achieved, cell damage is reduced, and blind single cell sorting is avoided. The method is easy to operate, the pretreatment process is convenient, and industrial application is facilitated; the sterilized pure water is used as a micro-liquid separation medium, the components are simple, the Raman spectrum is simple and uniform, and downstream microorganism Raman identification, separation and culture are facilitated; the method can be used as samples of intestinal microflora for sorting low-oxygen microorganisms such as saliva, excrement, urine, tongue coating and the like; the method can also be applied to samples of complex microbial communities, such as low-oxygen environments of deep sea, soil, sludge and the like, and sorting culture of unculturable microorganisms; the method can also be applied to screening and application of special functional microorganisms in the industrial fields of fermentation, pharmacy and the like; the method has great market application potential in micro-ecological research.

The invention discloses a feed containing astragalus polysaccharide and a preparation method thereof, and belongs to the field of feeds. The astragalus polysaccharide is added into the basic feed, so that the adverse effect of heat stress on the female rabbits can be effectively relieved, the conception rate of the female rabbits, the number of live litters and the average weight of the live litters can be increased, and the breeding economic benefits are improved while the reproductive performance is optimized and the growth of the young rabbits is promoted; the prepared feed can effectively improve the serum hormone level of animals and reduce the inflammatory factor level, meanwhile, the diversity of animal intestinal microorganisms under heat stress is effectively improved, a scientific basis is provided for precise feeding management of domestic rabbits in summer, and meanwhile, an important reference is provided for application of astragalus polysaccharide in the field of livestock and poultry anti-stress.

The invention discloses an intestinal microbial marker related to non-alcoholic fatty liver, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The microbial marker is prepared from one or more of streptococcus anginiae, bacteroides faecalis, bifidobacterium adolescentis and hispidaceae bacteria. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The invention further provides a product for diagnosing the non-alcoholic fatty liver disease, a prediction system for evaluating the risk that a to-be-detected object is a patient with the non-alcoholic fatty liver disease, and a computer program product related to the non-alcoholic fatty liver disease. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the non-alcoholic fatty liver disease, and provides a new tool for clinical diagnosis.

The invention belongs to the field of medicine, and discloses application of lactobacillus paracasei in preparation of medicine for repairing intestinal barrier function and treating AML (acute myeloid leukemia). Generally, gastrointestinal mucosal barriers, immune systems and nutrient absorption of AML patients receiving induced chemotherapy are severely damaged, and the factors severely destroy intestinal microbial balance, so that the progress of the disease course is promoted, and the occurrence rate of complications is increased. The invention finds that the lactobacillus paracasei has a remarkable effect in preparing the medicine for repairing the intestinal barrier function and treating AML (acute myeloid leukemia), and particularly, the lactobacillus paracasei can repair the intestinal barrier function and enhance the curative effect of cytarabine.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The invention discloses preparation and application of aquatic plant extracellular vesicles with an intestinal barrier regulating function, and belongs to the field of bioengineering technology and health food. The method mainly comprises the following steps: efficiently extracting aquatic plant extracellular vesicles by utilizing a tangential phase flow technology, and researching the functional activity of the aquatic plant extracellular vesicles. The obtained extracellular vesicles have good intestinal stability and biocompatibility, and also have significant antioxidant activity and anti-inflammatory effect. In a carbon tetrachloride induced chronic hepatic fibrosis model, the extracellular vesicles can reduce LPS (Lipopolysaccharide) generated by excessive reproduction of intestinal microorganisms from entering the liver by regulating intestinal tight junction protein, so that the liver inflammation is relieved. In addition, the extracellular vesicles can also regulate intestinal flora and immune barriers, and inflammatory response caused by chronic hepatic fibrosis is relieved through the intestinal liver axis. The extracellular vesicles prepared by the method have wide application prospects and economic benefits in anti-inflammatory drugs, nano-drug carriers and functional skin care products.